Oasmia Pharmaceutical AB signed a new five-year contract with Baxter BioPharma Solutions for global commercial manufacturing of Apealea. Technology transfer to Baxter is complete and manufacturing is planned to commence soon. Terms of the agreement were not disclosed.

Apealea will be manufactured at Baxter’s manufacturing site in Halle/Westfalen, Germany, a facility for cytotoxic contract manufacturing. Oasmia plans to shift its manufacturing at its site in Uppsala to focus on its other products, Doxophos and Docecal.

“This is an important step for Oasmia’s future growth and essential for our commercial success. We see this as an important step to accelerate the launch of Apealea and our other product candidates. Baxter is a very strong partner and enables us to meet the global demand of Apealea,” said Julian Aleksov, executive chairman of Oasmia Pharmaceutical AB.